Based on moderate quality evidence , due to concerns about risk of bias and imprecision , initiation of statin therapy within 14 days following ACS does not reduce death , myocardial infa rct ion , or stroke up to four months , but reduces the occurrence of unstable angina at four months following ACS .
Serious side effects were rare
BACKGROUND The early period following the onset of acute coronary syndrome ( ACS ) represents a critical stage of coronary heart disease , with a high risk of recurrent events and deaths .
The short-term effects of early treatment with statins on patient-relevant outcomes in patients suffering from ACS are unclear .
This is an up date of a review previously published in 2011 .
OBJECTIVES To assess the effects , both harms and benefits , of early administered statins in patients with ACS , in terms of mortality and cardiovascular events .
Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome (JAPAN-ACS): rationale and design.
BACKGROUND Many trials have shown that 3-hydroxy-3-methyl-glutaryl coenzyme A ( HMG-CoA ) reductase inhibitors reduce the incidence of cardiovascular events and mortality . One method of decreasing the incidence of cardiovascular events could be to reduce the progression of coronary atherosclerosis , and a recent study found that atorvastatin can cause coronary plaque to regress . To generalize this finding , using conventional HMG-CoA reductase inhibitors at many Japanese centers , r and omized trials of pitavastatin and atorvastatin will be conducted with patients with acute coronary syndrome ( ACS ) . METHODS AND RESULTS Patients with ACS who have undergone successful percutaneous coronary intervention under intravascular ultrasound guidance will be studied . They will be r and omly allocated to pitavastatin or atorvastatin groups and followed up for 8 - 12 months . The primary endpoint will be the percent change in coronary plaque volume , and secondary endpoints will include absolute changes in coronary plaque volume , serum lipid levels and inflammatory markers . The safety profile will also be evaluated . CONCLUSIONS This study will examine the ability of HMG-CoA reductase inhibitors to regress coronary plaque in Japanese patients with ACS and the findings should help to improve the prognosis of such patients and clarify the involved mechanisms
Based on moderate quality evidence , due to concerns about risk of bias and imprecision , initiation of statin therapy within 14 days following ACS does not reduce death , myocardial infa rct ion , or stroke up to four months , but reduces the occurrence of unstable angina at four months following ACS .
Serious side effects were rare
BACKGROUND The early period following the onset of acute coronary syndrome ( ACS ) represents a critical stage of coronary heart disease , with a high risk of recurrent events and deaths .
The short-term effects of early treatment with statins on patient-relevant outcomes in patients suffering from ACS are unclear .
This is an up date of a review previously published in 2011 .
OBJECTIVES To assess the effects , both harms and benefits , of early administered statins in patients with ACS , in terms of mortality and cardiovascular events .